Organoid co-cultures with autologous T cells to assess toxicity and efficacy of bispecific antibodies
Immunotherapies have demonstrated great success in clinical treatment for certain types of cancer. However, the lack of preclinical models that preserve patient-specific tumor antigen expression and recapitulate the immune cell response to tumors in vivo is hindering the successful development of novel therapeutic strategies.
Download this poster to discover:
- The establishment of a non-small cell lung cancer (NSCLC) organoid and tumor-infiltrating lymphocyte (TIL) co-culture platform
- The available readouts that provide an indication of T-cell bispecific (TCB) activity
- The potential of NSCLC organoid-TIL co-culture platform in assessing the toxicity and efficacy of bispecific antibodies targeting tumor antigens.